anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention discloses a traditional Chinese medicine plaster for improving body immunity in three periods of hot season and a preparation method thereof, and belongs to the field of formulae of medicines for improving the body immunity and preparation methods thereof. On the theoretical basis of treating winter diseases in summer, different traditional Chinese medicines are combined in the three periods of the hot season, so the repeated cold, rhinitis, chronic cough, rheumatism, frail health and the like caused by low human immune function because of insufficient yang qi can be treated. The traditional Chinese medicine plaster comprises the following raw materials of artificial musk, asarum, euphorbia kansui, semen brassicae, corydalis, pericarpium zanthoxyli, radix aconiti lateralis preparata, musk and raw pinellia ternate. The preparation method comprises the following steps of crushing the raw materials into 200-mesh fine powder according to ratios, using fresh ginger juice, adding the fine powder into the fresh ginger juice, stirring and uniformly mixing, subpackaging, and pressing, so as to prepare the medicine storehouse type traditional Chinese medicine plaster. The traditional Chinese medicine plaster is used by a method that the traditional Chinese medicine plaster is applied at the first day of each of the three periods of the hot season, and is applied for three times in total. The traditional Chinese medicine plaster has the advantages that the dosage of the plaster is accurate, the convenience in use is realized, and the compliance of a patient in use is better; especially, the cost is lower, and the long-time therapy effect is good, so the traditional Chinese medicine plaster can be accepted by the populations.
Curcumin has been studied as the main bioactive component of the rhizome of the herb Curcuma longa, known as turmeric, and is associated to potential health effects and benefits. Other bioactive components have also been identified, called the curcuminoid group. Curcuminoids are natural yellow-orange pigments and hydrophobic polyphenols derived from. Extracts of turmeric generally contain 75-80% curcumin, 15-20% demethoxycurcumin (DMC), and 0-10% bisdemethoxycurcumin (BDMC). Curcumin and curcuminoids have been extensively investigated due to their antioxidant and anti-inflammatory properties, notably regarding their potential efficacy in modulating various health conditions.

In the present trial, the aim is to assess the bioavailability of curcuminoids in different food matrix formulations, the capsule format being the reference matrix, with a hypothesis of equivalence. The primary objective of the study is to assess the plasmatic concentration profile of total curcuminoids (curcumin, DMC, BDMC and their metabolites) on a 24-hour period after consumption of five different food matrix formulations containing TPG in comparison to the dietary supplement capsule formulation.
Animals and their associated microbiota share long evolutionary histories. However, it is not always clear how host genotype and microbiota interact to affect phenotype. We applied a hologenomic approach to explore how host-microbiota interactions shape lifetime growth and parasite infection in farmed Atlantic salmon (Salmo salar). Multi-omics data sets were generated from the guts of 460 salmon, 82% of which were naturally infected with an intestinal cestode. A single Mycoplasma bacterial strain, MAG01, dominated the gut metagenome of large, non-parasitized fish, consistent with previous studies showing high levels of Mycoplasma in the gut microbiota of healthy salmon. While small and/or parasitized salmon also had high abundance of MAG01, we observed increased alpha diversity in these individuals, driven by increased frequency of low-abundance Vibrionaceae and other Mycoplasma species that carried known virulence genes. Colonization by one of these cestode-associated Mycoplasma strains was associated with host individual genomic variation in long non-coding RNAs. Integrating the multi-omic data sets revealed coordinated changes in the salmon gut mRNA transcriptome and metabolome that correlated with shifts in the microbiota of smaller, parasitized fish. Our results suggest that the gut microbiota of small and/or parasitized fish is in a state of dysbiosis that partly depends on the host genotype, highlighting the value of using a hologenomic approach to incorporate the microbiota into the study of host-parasite dynamics.IMPORTANCEStudying host-microbiota interactions through the perspective of the hologenome is gaining interest across all life sciences. Intestinal parasite infections are a huge burden on human and animal health; however, there are few studies investigating the role of the hologenome during parasite infections. We address this gap in the largest multi-omics fish microbiota study to date using natural cestode infection of farmed Atlantic salmon. We find a clear association between cestode infection, salmon lifetime growth, and perturbation of the salmon gut microbiota. Furthermore, we provide the first evidence that the genetic background of the host may partly determine how the gut microbiota changes during parasite-associated dysbiosis. Our study therefore highlights the value of a hologenomic approach for gaining a more in-depth understanding of parasitism.
Among 2,633 patients treated with ZOMIG Tablets in the active and placebo controlled trials, no patients withdrew for reasons related to adverse events, but as patients treated a single headache in these trials, the opportunity for discontinuation was limited. In a long-term, open label study where patients were allowed to treat multiple migraine attacks for up to 1 year, 8% (167 out of 2,058) withdrew from the trial because of adverse experience. The most common events were paresthesia, asthenia, nausea, dizziness, pain, chest or neck tightness or heaviness, somnolence, and warm sensation.

Table 2 lists the adverse events that occurred in ≥ 2% of the 2,074 patients in any one of the ZOMIG 1 mg, ZOMIG 2.5 mg or ZOMIG 5 mg Tablets dose groups of the controlled clinical trials. Only events that were more frequent in a ZOMIG Tablets group compared to the placebo groups are included. The events cited reflect experience gained under closely monitored conditions of clinical trials in a highly selected patient population. In actual clinical practice or in other clinical trials, these frequency estimates may not apply, as the conditions of use, reporting behavior, and the kinds of patients treated may differ.

Several of the adverse events appear dose related, notably paresthesia, sensation of heaviness or tightness in chest, neck, jaw, and throat, dizziness, somnolence, and possibly asthenia and nausea.

ZOMIG is generally well tolerated. Across all doses, most adverse reactions were mild and transient and did not lead to long-lasting effects. The incidence of adverse events in controlled clinical trials was not affected by gender, weight, or age of the patients; use of prophylactic medications; or presence of aura. There were insufficient data to assess the impact of race on the incidence of adverse events.
Levetiracetam tablets USP, 250 mg are Blue film coated, Capsule shaped, biconvex tablets debossed with I on the left side of bisect and G on the right side of bisect on one side and 246 on other. They are supplied in containers of 120 tablets (NDC 76282-246-12).

Levetiracetam tablets USP, 500 mg are Yellow film coated, Capsule shaped, biconvex tablets debossed with I on the left side of bisect and G on the right side of bisect on one side and 247 on other. They are supplied in containers of 120 tablets (NDC 76282-247-12).

Levetiracetam tablets USP, 750 mg are Pink film coated, Capsule shaped, biconvex tablets debossed with I on the left side of bisect and G on the right side of bisect on one side and 248 on other. They are supplied in containers of 120 tablets (NDC 76282-248-12).
All patients who underwent cardiac catheterization for assessment of CAD at Keelung Chang Gung Memorial Hospital between 1992 and 2004 with continuous serum creatinine values measured before admission were included in this analysis. Data were obtained from medical records of the database center of our institution. Demographic and clinical data were assessed. The age, sex, body mass index (BMI), body surface area (BSA), underlying comorbidities, CAD risk factors (including diabetes mellitus, hypertension, dyslipidemia, smoking, and obesity, defined as a BMI \> 30) and clinical presentation were included in this study. Hemodynamic parameters including the systolic and diastolic blood pressure, heart rate and left ventricular ejection fraction were also obtained. Coronary angiography was performed using a low-osmolarity non-ionic contrast medium (iodixanol) by experienced cardiologist. Coronary artery disease was defined as a 50% or greater lumen narrowing of a major epicardial artery or its branches. A left main stenosis of 50% or greater was regarded as equivalent to 2-vessel disease. Blood samples were collected during admission before angiographic procedure. Values of hemoglobin, white blood cells, platelet, high sensitivity C-reactive protein (hs-CRP) and troponin I was included. The treatment modality was divided into three categories: medical, percutaneous coronary intervention (PCI, including balloon angioplasty with or without stent placement) and coronary artery bridge graft (CABG) on the basis of clinical condition and angiographic finding. The outcome was followed-up until 12 months after angiographic procedure. The estimated total study patient number is approximately 1000 patients.
A bone marrow isolate rich in one or more connective tissue growth components, methods of forming the isolate, and methods of promoting connective tissue growth using the isolate are described. A biological sample comprising bone marrow is centrifuged to separate the sample into fractions including a fraction rich in connective tissue growth components. The fraction rich in connective tissue growth components is then isolated from the separated sample. The isolate can be used directly or combined with a carrier and implanted into a patient at a tissue (e.g., bone) defect site. The biological sample can comprise bone marrow and whole blood. The isolate can be modified (e.g., by transfection with a nucleic acid encoding an osteoinductive polypeptide operably linked to a promoter) prior to application to the tissue defect site. The isolate can be made and applied to the tissue defect site in a single procedure (i.e., intraoperatively).
Treatment with irbesartan 300mg for 4 weeks. IF ABP\>135/85 mmHg add HCZ 12.5 mg.
PURPOSE:To obtain a sensor which can be used for measurement repeatedly in an enzyme immunoassay (EIA) while being excellent in reproducibility, by mounting an antibody immobilized film, obtained by batch immobilization of antibodies, on an oxygen electrode. CONSTITUTION:This sensor is produced by mounting an antibody immobilized film 4, obtained by batch immobilization of antibodies, outside an oxygen transmitting film 3 of an oxygen electrode 2 of galvanic type, polarography type or the like. The sensor thus obtained is incorporated into a reaction cell 1 to be used for measurement by a flow method in which an immunological reaction liquid, an oxygen substrate liquid or a cleaning liquid are introduced sequentially into the reaction cell 1 or by a method wherein the reaction cell 1 is immersed sequentially into a container holding these liquids. The oxygen transmitting film 3 of the oxygen electrode 2 herein used is a polyethylene film, a teflon film or the like. A measurable antigen is, for example, serum protein such as insulin and villous gonadotropin. When the antigen is measured, the immobilized film 4 obtained by batch immobilization of corresponding antibodies is used. Measurement is preferably performed by the sandwiching method.
OBJECTIVE: Dystonia is among the most common pediatric movement disorders and can manifest with a range of debilitating symptoms, including sleep disruptions. The duration and quality of sleep are strongly associated with quality of life in these individuals and could serve as biomarkers of dystonia severity and the efficacy of interventions such as deep brain stimulation (DBS). Thus, this study investigated sleep duration and its relationship to disease severity and DBS response in pediatric dystonia.
METHODS: Actigraphs (wearable three-axis accelerometers) were used to record multiday sleep data in 22 children with dystonia, including 6 patients before and after DBS implantation, and age- and sex- matched healthy controls. Data were preprocessed, and metrics of sleep duration and quality were extracted. Repeated-measures statistical analyses were used.
RESULTS: Children with dystonia slept less than typically developing children (p = 0.009), and shorter sleep duration showed trending correlation with worse dystonia severity (r = -0.421, p = 0.073). Of 4 patients who underwent DBS and had good-quality data, 1 demonstrated significantly improved sleep (p < 0.001) postoperatively. Reduction in dystonia severity strongly correlated with increased sleep duration after DBS implantation (r = -0.965, p = 0.035).
CONCLUSIONS: Sleep disturbances are an underrecognized marker of pediatric dystonia severity, as well as the effectiveness of interventions such as DBS. They can serve as objective biomarkers of disease burden and symptom progression after treatment.
NEW MATERIAL:A compound expressed by formula I [A is formula II, III or IV (the broken line represents alpha-configuaconfiguration; symbol represents beta-configuration; the wavy line represents alpha-, beta-configuration or a mixture thereof; the bond between carbon atoms at the 12- and 13- positions and the bond between carbon atoms at the 14- and 15-positions informula II are respectively trans- or cis-configuration or a mixture thereof; the bond between carbon atoms at the 9- 10-positions in formula II is cis-configuration; the bond between carbon atoms at the 9- and 10-positions and the bond between carbon atoms at the 13- and 14-positions in formula IIIare respectively cis- or trans-configuration or mixture thereof; the bond between carbon atoms at the 13- and 14-positions in formula IV is trans-configuration); X is ethylene, etc.; R<1> is H or 1-4C alkyl; R<2> is 2-6C alkyl substituted by 1-3 OH groups; R<3> is single bond or 1-5C alkylene; R<4> is 1-8C alkyl, etc.] or a cyclodextrin clathrate compound thereof. USE:An antitumor agent having almost no pharmacological action unique to prostaglandin. PREPARATION:A compound expressed by formula V (R<5> is 1-ethoxyethyl, etc.) is hydrolyzed under acidic conditions to give a compound expressed by formula  I (A is expressed by formula III) or a compound expressed by formula VI is hydrolyzed under acidic conditions to afford the compound expressed by the formula I (A is expressed by formula IV).
A composition for treating or preventing diarrhea is provided to prevent side effects such as exhaustion or weight loss for the medication period and to have no reduction of the weight increment particularly in case of using in domestic animals. A composition for treating or preventing diarrhea comprises taro extracts, broadleaf plantain extracts, Lonicera japonica Thunb extracts, chestnut extracts and Diospyros kaki extracts. The taro is the taro stem. The broadleaf plantain is 1 or greater selected from a group consisting of leaf of broadleaf plantain, and stem and root. The Lonicera japonica Thunb is the leaf and stem of Lonicera japonica Thunb or their mixture. The chestnut is the inside skin.
Quantitative methods are used to determine antimicrobial minimum inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MICs should be determined using a standardized procedure. Standardized procedures are based on a dilution method4 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of sulfamethoxazole/trimethoprim powder. The MIC values should be interpreted according to the following criteria:

a. These interpretative standards are applicable only to broth microdilution susceptibility tests with Haemophilus influenzae using Haemophilus Test Medium (HTM).4

b. These interpretative standards are applicable only to broth microdilution susceptibility tests using cation-adjusted Mueller-Hinton broth with 2% to 5% lysed horse blood.4

A report of "Susceptible" indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of "Intermediate" indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of "Resistant" indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Mitochondrial diseases are rare genetic disorders often accompanied by severe sleep disorders. We present the case of a 12-year-old boy diagnosed with a severe primary mitochondrial disease, exhibiting ataxia, spasticity, progressive external ophthalmoplegia, cardiomyopathy and severely disrupted sleep, but no cognitive impairment. Interestingly, his parents reported improved sleep during night train rides. Based on this observation, we installed a rocking bed in the patient's bedroom and performed different interventions, including immersive multimodal vestibular, kinesthetic and auditory stimuli, reminiscent of the sensory experiences encountered during train rides. Over a 5-month period, we conducted four 2-week nocturnal interventions, separated by 1-week washout phases, to determine the subjectively best-perceived stimulation parameters, followed by a final 4-week intervention using the optimal parameters. We assessed sleep duration and quality using the Mini Sleep Questionnaire, monitored pulse rate changes and used videography to document nocturnal interactions between the patient and caregivers. Patient-reported outcome measures, clinical examinations and personal outcomes of specific interests were used to document daytime sleepiness, restlessness, anxiety, fatigue, cognitive performance and physical posture. In the final 4-week intervention, sleep duration increased by 25%, required caregiver interactions reduced by 75%, and caregiving time decreased by 40%. Subjective fatigue, assessed by the Checklist Individual Strength, decreased by 40%, falling below the threshold of severe fatigue. Our study suggests that rocking beds could provide a promising treatment regime for selected patients with persistent severe sleep disorders. Further research is required to validate these findings in larger patient populations with sleep disorders and other conditions.
A method and system of forming a pharmaceutical dosage form within a portion of a blister packaging. The method includes the steps of providing a blister packaging for the dosage form with depressions. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited into a substantially uniform powder layer within the depressions. A binding liquid is then deposited in a pattern on the powder layer within the depressions, to bind the particles of the powder layer and form an incremental wetted powder layer. Excess solvent in the binding material can be removed to form an incremental bound layer. These steps are repeated in sequence at least one or more times to form the pharmaceutical dosage form within the blister packaging.
PURPOSE: A composition containing bacteriocin cerein 13061 for killing germ is provided to replace antibiotics used in the food industry or livestock industry. CONSTITUTION: A polypeptide with a bacteriocin activity contains an amino acid sequence of sequence number 1 or 2. A polynucleotide encoding the amino acid of sequence number 1 has a nucleic acid sequence of sequence number 3. A polynucleotide encoding the amino acid of sequence number 2 has a nucleic acid sequence of sequence number 5. A composition for killing germ independently contains the polypeptide of sequence number 1 or 2 or a combination of the polypeptides. The composition contains a culture of Bacillus cereus ATCC 13061 as an active ingredient.
FIELD: medicine, cosmetology, food industry. SUBSTANCE: invention deals with chitosan-based biologically active composition being the powerful stimulator in healing surface wounds, such as burns, ulcers and others. It, also, removes skin irritation, quickly restores cutaneous function in case of bedsores in severe patients. The suggested composition of biologically active composition contain chitosan gel or chitosan suspension at spheroidal nanogranules size being not above 100 nm and ions of precious metals at the quantity of 10 wt.%, not higher. The invention enables to achieve improved quality of biologically active composition due to increasing its penetrating capacity and healing and disinfecting action. EFFECT: higher efficiency. 2 cl, 5 ex
The control group will receive six PT sessions as "standard care". The first session is 60 minutes and the following sessions are 30 minutes. In regular clinical practice, "standard care" for people with osteoporosis includes measures such as home exercise programs, mobilizations, soft tissue techniques, or training with gym equipment. The HEP in the control group is based on the physical assessment of the physical therapist. The therapists in the control group do not have any restrictions for the exercises chosen. The participants must attend at least 4 out of 6 sessions of the control program.
The intervention group will participate in face-to-face video telemedicine visits, in addition to routine annual visits to the Spina Bifida Clinic. These 30-minute visits will occur at 2 weeks, 3 months, 6 months and 9 months from last in-person clinic appointment. The visits will consist of structured counseling using a plan-do-study-act cycle approach to incrementally adopt elements of a well-planned transition. Using qualitative notes from each session, we will identify common themes or challenges across patients and develop adjunctive education, support, and monitoring tools for patients and families in transition.
Background The growing burden of gastroesophageal reflux disease (GERD) still impacts healthcare costs intensively. Although the treatment with proton pump inhibitor (PPI) is effective in many cases, surgical treatment remains relevant due to a large amount of PPI refractory GERD. Laparoscopic fundoplication (LF) is considered as standard procedure, but this type of surgery is linked to side effects as dysphagia, gas bloating and inability to belch. Especially patients with ineffective esophageal motility (IEM) are prone to postoperative dysphagia after LF. Lower esophageal sphincter electrical stimulation (LES-EST) was introduced as an alternative technique to avoid side effects of LF. Rodriquez et al. have bee demonstrated that LES-EST significantly raises the LES pressure and improved GERD symptoms such as heartburn and regurgitation. The advantage of this procedure is that the anatomy of the esophageal-gastric junction is not altered dramatically. Notably, patients with severely disordered esophageal peristalsis will benefit from this low-risk profile.

After successful implementation of this technique at the Medical University of Vienna (EK 1149/2014), a prospective evaluation of data with the well established gastroesophageal reflux disease - health-related quality of life is next. Patients with esophageal motility disorder, who undergo LES-EST, will be investigated towards side effects such as gas-bloating, inability to belch, flatulence and dysphagia.